related documents
- Early real-world effectiveness of secukinumab in the treatment of psoriasis in Canada: Retrospective analysis of patient support program data Conferences
- Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab Conferences
- Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: An area under the curve analysis Conferences